Newsletter
1. Marksans Pharma gets UK nod for diabetes drug 💊
Marksans' UK arm Relonchem Ltd got approval to sell a diabetes drug in liquid form.
The medication is called Metformin Hydrochloride Oral Solution, a liquid formulation used to manage type 2 diabetes,
Zoom out: type 2 diabetes affects over 100 million Indians. While tablets are the most common form, oral solutions are crucial for elderly patients, children, or those who have trouble swallowing pills.
In India, the market for oral liquid diabetes medicines is still small but growing steadily with the rise in senior citizens and diabetic cases. With this UK approval, Marksans is opening up a high-margin niche where fewer players mean better pricing power.
2. Reliance Power’s solar charge ☀️
Reliance Power jumped 11% after bagging a 350 MW solar + 175 MW storage project from SJVN, sending the stock to a 10-year high.
A 350 MW solar project can power over 2 lakh homes annually, generating around 613 million units of clean electricity.
The project will add 600 MW of solar DC capacity and 700 MWh of storage to Reliance Power’s clean energy portfolio. With this, the company now boasts India’s largest pipeline in the integrated Solar + BESS segment, totaling 2.4 GW of solar and 2.5 GWh of storage.
Zoom out: Reliance Power’s stock has been on a tear, up 50% in just a month and 140% over the past year. Friday’s surge came with 2x the usual trading volumes, showing rising investor interest.
